Unmedicated Depressed Women Show Reduced Heat Tolerance Compared to SSRI Users

A groundbreaking study from Penn State University’s Department of Kinesiology offers fresh insight into how major depressive disorder and its treatments affect women’s physiological responses to extreme heat. Contrary to widespread concerns that selective serotonin reuptake inhibitors (SSRIs) may increase heat-related health risks, new evidence reveals these medications might actually enhance heat tolerance in women with depression.

The human body regulates core temperature mainly through two mechanisms: sweating and increasing blood flow to the skin to dissipate heat. Kathleen “Kat” Fisher, lead author and recent Ph.D. graduate, explains that depression disrupts these processes. Her experimental study demonstrated that unmedicated depressed women exhibit delayed onset of sweating and a blunted vasodilatory response — the ability of blood vessels to widen and increase blood flow to the skin. These impairments reduce the efficiency of heat dissipation, potentially increasing vulnerability during heat exposure.

The research team recruited 64 women in their twenties, divided into four groups: non-depressed controls, women with depression not on medication, women on SSRI treatment, and women taking serotonin-norepinephrine reuptake inhibitors (SNRIs). Participants swallowed an ingestible temperature sensor to continuously monitor core temperature. They then wore a specialized suit circulated with heated water, gradually increasing skin temperature to approximately 100°F, mimicking a passive heat stress environment similar to sitting in a hot tub.

Results revealed stark physiological differences among the groups. Women with untreated depression showed significantly slower onset of sweating and reduced efficiency in increasing skin blood flow compared to non-depressed counterparts. However, those treated with SSRIs demonstrated normalized responses, comparable to the healthy control group, suggesting restoration of thermoregulatory mechanisms. Intriguingly, women taking SNRIs behaved similarly to untreated depressed women, indicating that not all antidepressants confer the same thermoregulatory benefits.

Importantly, no differences in blood pressure were observed across any groups, suggesting the variations in heat responses were independent of cardiovascular pressure regulation. These findings challenge prevalent narratives that SSRIs inherently increase heat-related health risks. Instead, SSRIs appear to counteract the detrimental impact of depression on vascular function and sweating, improving heat resilience.

W. Larry Kenney, study co-author and professor of physiology, emphasized the significance of this research in correcting misconceptions. He notes that much of the evidence linking medications to heat vulnerability is anecdotal or weak. This rigorous experimental approach lays a scientific foundation showing that SSRIs ameliorate temperature regulation deficits induced by depression rather than exacerbate them.

Given that depression affects about 10% of the U.S. population and is twice as common among women, understanding how antidepressants interact with physiological heat responses holds critical public health importance, especially as global temperatures rise. This study adds a crucial dimension to clinical guidance on medication management during heat waves and could influence future recommendations in heat safety protocols.

As climate change continues to increase the frequency and intensity of heat events, such insights refine our understanding of individual risk factors and could ultimately save lives. The research team calls for further investigation into the mechanisms by which different antidepressants modulate thermoregulation and emphasizes the need for personalized approaches to managing heat risk in vulnerable populations.